Página principal > Resultados de la búsqueda: Kater, A P.
  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Resultados globales: 2 registros encontrados en 0.01 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
1.
17 p, 1.2 MB Impact of Minimal Residual Disease on Progression-Free Survival Outcomes after Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study / Munir, Talha (St James's Hospital) ; Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Owen, Carolyn (Tom Baker Cancer Centre) ; Follows, George (Addenbrookes Hospital (Cambridge, Regne Unit)) ; Benjamini, Ohad (Sheba Medical Center) ; Janssens, Ann (UZ Leuven Gasthuisberg) ; Levin, Mark-David (Albert Schweitzer Hospital) ; Osterborg, Anders (Karolinska University Hospital and Karolinska Institutet (Suecia)) ; Robak, Tadeusz (Medical University of Lodz. Copernicus Memorial Hospital) ; Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ; Stevens, Don (Norton Cancer Institute) ; Voloshin, Sergey (Russian Scientific and Research Institute of Hematology and Transfusiology) ; Vorobyev, Vladimir (S.P. Botkin Moscow City Clinical Hospital) ; Yagci, Munci (Gazi Universitesi Tip Fakultesi) ; Ysebaert, Loic (Institut Universitaire du Cancer Toulouse Oncopole) ; Qi, Keqin (Janssen Research & Development) ; Qi, Qianya (Janssen Research & Development) ; Parisi, Lori (Janssen Research & Development) ; Srinivasan, Srinivasan (Oncology Translational Research. Janssen Research & Development) ; Schuier, Natasha (Janssen Research & Development) ; Baeten, Kurt (Janssen Research & Development) ; Howes, Angela (Janssen Research & Development) ; Caces, Donne Bennett (Janssen Research & Development) ; Niemann, Carsten U (Rigshospitalet Copenhagen University Hospital) ; Kater, Arnon P. (Amsterdam Medical Centers. University of Amsterdam)
PURPOSEIn GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). [...]
2023 - 10.1200/JCO.22.02283
Journal of Clinical Oncology, Vol. 41 Núm. 21 (20 2023) , p. 3689-3699  
Registro completo - Creative Commons
2.
11 p, 693.2 KB ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation / Malcikova, J. (Brno, Czech Republic) ; Tausch, E. (Ulm, Germany) ; Rossi, Davide (Bellinzona, Switzerland) ; Sutton, L. A. (Stockholm, Sweden) ; Soussi, T. (Stockholm, Sweden) ; Zenz, Thorsten (Zürich, Switzerland) ; Kater, A. P. (Amsterdam, The Netherlands) ; Niemann, C. U. (Copenhagen, Denmark) ; González De Castro, David (Belfast, UK) ; Davi, F. (Paris, France) ; Gonzalez Diaz, M. (Salamanca, Spain) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Gaidano, Gianluca (Novara, Italy) ; Stamatopoulos, K. (Thessaloniki, Greece) ; Rosenquist, R. (Stockholm, Sweden) ; Stilgenbauer, S. (Ulm, Germany) ; Ghia, Paolo (Milan, Italy) ; Pospisilova, S. (Brno, Czech Republic) ; Universitat Autònoma de Barcelona
In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with resistance to chemoimmunotherapy and a particularly dismal clinical outcome. [...]
2018 - 10.1038/s41375-017-0007-7
Leukemia, Vol. 32 (february 2018) , p. 1070-1080  
Registro completo - Creative Commons

Vea también: autores con nombres similares
1 Kater, A. P.
1 Kater, A.P.
1 Kater, Arnon P.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos